Betulinic acid (Synonyms: Lupatic acid; Betulic acid)

Name: Betulinic acid
Brand: MedChemExpress
SKU: HY-10529
Rating: 5.0 (35 reviews)

Cat. No.: HY-10529 Purity: 99.88%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC₅₀ of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties. Betulinic acid can cross the blood-brain barrier.

For research use only. We do not sell to patients.

CAS No. : 472-15-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 35 publication(s) in Google Scholar

Other Forms of Betulinic acid:

Betulinic acid-d₃ In-stock
Betulinic acid (Standard) In-stock

35 Publications Citing Use of MCE Betulinic acid

Histological Imaging/Staining

Bio/Physico-chemical Assay

In Vivo Efficacy Study

: Betulinic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]; Serum levels of ALT and AST were measured to assess liver function in Betulinic acid (BA) (20, 50 mg/kg, i.g.) treatment group significantly reduced, providing a biochemical evaluation of hepatic injury.

: Betulinic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]; Representative images illustrating the morphological alterations in the liver of mice from different treatment groups, highlighting the effects of Betulinic acid (BA) (20, 50 mg/kg, i.g.) on hepatic appearance.

: Betulinic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 May 1;12(8):3656-3675.; Betulinic acid (20 μM) significantly reversed the down-regulation of nNOS and CAPON expression induced by fluoxetine.

: Betulinic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 11;17(4):1138-1152. [Abstract]; Longitudinal spinal cord sections from the indicated groups at day 14 were analyzed by HE staining and Masson staining.

: Betulinic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 11;17(4):1138-1152. [Abstract]; With Betulinic acid (BA) (20 mg/kg, i.p.) treatment, animals had higher neuronal MAP2 expression, and more SYN-positive synapses onto ventral motor neurons compared with the untreated SCI group.

: Betulinic acid purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Sep 13;10:1017. [Abstract]; Immunofluorescence is performed to determine the LC3II expression level to show the autophagosomes in the cells of the skin flaps: autophagosomes (green) in the dermis in area II; nuclei counterstained with DAPI (blue).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II DNA gyrase

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC₅₀ of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties^[1]^[2]^[3]^[4]. Betulinic acid can cross the blood-brain barrier^[5].

IC₅₀ & Target^[1]^[4]^[5]

Topoisomerase I

5 μM (IC₅₀)

HIV-1

1.4 μM (EC₅₀)

NF-κB

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	14.04 μM Compound: BA	Cytotoxicity against mouse 4T1 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against mouse 4T1 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
518A2	EC₅₀	11.9 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 27142753]
518A2	EC₅₀	11.9 μM Compound: BA	Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
518A2	EC₅₀	11.9 μM Compound: Betulinic acid	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
518A2	EC₅₀	13.6 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28169163]
518A2	EC₅₀	9.4 μM Compound: 1	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26547057]
518A2	EC₅₀	9.4 μM Compound: 4; BA	Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
518A2	EC₅₀	9.4 μM Compound: 5	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	EC₅₀	9.4 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26750249]
518A2	EC₅₀	9.4 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 27017553]
518A2	EC₅₀	9.4 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
518A2	IC₅₀	0.33 μM Compound: 1	Antitumor activity against human 518A2 cells by SRB assay Antitumor activity against human 518A2 cells by SRB assay	[PMID: 31499360]
518A2	IC₅₀	11.9 μM Compound: 2, BA	Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
518A2	IC₅₀	11.9 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 20034802]
518A2	IC₅₀	11.9 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
518A2	IC₅₀	11.9 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
518A2	IC₅₀	11.9 μM Compound: BA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24161703]
518A2	IC₅₀	14.8 μM Compound: 1	Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
518A2	IC₅₀	8.13 μM Compound: 1	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 20451375]
518A2	IC₅₀	8.13 μM Compound: 1	Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
8505C	EC₅₀	6.7 μM Compound: BA	Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
8505C	EC₅₀	6.7 μM Compound: Betulinic acid	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
8505C	IC₅₀	0.33 μM Compound: 1	Antitumor activity against human 8505C cells by SRB assay Antitumor activity against human 8505C cells by SRB assay	[PMID: 31499360]
8505C	IC₅₀	12.63 μM Compound: 1	Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
8505C	IC₅₀	6.7 μM Compound: 2, BA	Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
8505C	IC₅₀	6.7 μM Compound: BA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 20034802]
8505C	IC₅₀	6.7 μM Compound: BA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
8505C	IC₅₀	6.7 μM Compound: BA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
8505C	IC₅₀	6.7 μM Compound: BA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24161703]
8505C	IC₅₀	7.26 μM Compound: 1	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 20451375]
A-375	EC₅₀	12 μM Compound: BA	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A-375	EC₅₀	17.1 μM Compound: BA	Cytotoxicity against human A375 cells after 96 hrs by SRB assay Cytotoxicity against human A375 cells after 96 hrs by SRB assay	[PMID: 29960206]
A-375	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A-375	IC₅₀	22 μM Compound: 1	Cytotoxicity against human A375 cells after 72 hrs by MTS assay Cytotoxicity against human A375 cells after 72 hrs by MTS assay	[PMID: 20719505]
A-375	IC₅₀	43.7 μM Compound: BA	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28368586]
A-375	IC₅₀	51 μM Compound: 7	Antiproliferative activity against human A375 cells after 72 hrs by MTS assay Antiproliferative activity against human A375 cells after 72 hrs by MTS assay	[PMID: 19286375]
A-431	IC₅₀	12.6 μM Compound: 1	Cytotoxicity against human A431 cells after 96 hrs by SRB assay Cytotoxicity against human A431 cells after 96 hrs by SRB assay	[PMID: 20451375]
A-431	IC₅₀	12.6 μM Compound: 1	Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A-431	IC₅₀	15.4 μM Compound: BA	Cytotoxicity against human A431 cells after 96 hrs by SRB assay Cytotoxicity against human A431 cells after 96 hrs by SRB assay	[PMID: 20034802]
A-431	IC₅₀	15.4 μM Compound: BA	Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
A-431	IC₅₀	15.4 μM Compound: BA	Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
A2780	EC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 27142753]
A2780	EC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 29960206]
A2780	EC₅₀	11 μM Compound: Betulinic acid	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
A2780	EC₅₀	12.7 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28169163]
A2780	EC₅₀	12.7 μM Compound: BA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A2780	EC₅₀	12.7 μM Compound: BA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A2780	EC₅₀	12.7 μM Compound: BA	Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
A2780	EC₅₀	8.8 μM Compound: 1	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26547057]
A2780	EC₅₀	8.8 μM Compound: 4; BA	Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A2780	EC₅₀	8.8 μM Compound: 5	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	8.8 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26750249]
A2780	EC₅₀	8.8 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 27017553]
A2780	EC₅₀	8.8 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	8.8 μM Compound: BA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A2780	EC₅₀	9.7 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
A2780	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A2780	IC₅₀	0.33 μM Compound: 1	Antitumor activity against human A2780 cells by SRB assay Antitumor activity against human A2780 cells by SRB assay	[PMID: 31499360]
A2780	IC₅₀	11 μM Compound: 2, BA	Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
A2780	IC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 20034802]
A2780	IC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
A2780	IC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
A2780	IC₅₀	11 μM Compound: BA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24161703]
A2780	IC₅₀	11.07 μM Compound: 1	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 20451375]
A2780	IC₅₀	11.07 μM Compound: 1	Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A2780	IC₅₀	8.75 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
A2780	IC₅₀	>= 20 μg/mL Compound: 7	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 12662105]
A549	EC₅₀	14.8 μM Compound: Betulinic acid	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
A549	EC₅₀	14.9 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 27142753]
A549	EC₅₀	14.9 μM Compound: BA	Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
A549	EC₅₀	17.1 μM Compound: 1	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26547057]
A549	EC₅₀	17.1 μM Compound: 4; BA	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A549	EC₅₀	17.1 μM Compound: 5	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	EC₅₀	17.1 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26750249]
A549	EC₅₀	17.1 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 27017553]
A549	EC₅₀	17.1 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	EC₅₀	7.6 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28169163]
A549	ED₅₀	7.7 μg/mL Compound: BA (Betulinic acid)	Cytotoxic activity towards A-549 cells Cytotoxic activity towards A-549 cells	[PMID: 12951080]
A549	ED₅₀	> 10 μg/mL Compound: Betulinic acid	Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
A549	IC₅₀	0.33 μM Compound: 1	Antitumor activity against human A549 cells by SRB assay Antitumor activity against human A549 cells by SRB assay	[PMID: 31499360]
A549	IC₅₀	10.3 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	10.3 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 19115839]
A549	IC₅₀	10.3 μM Compound: 3	Cytotoxicity against human A549 cells by resazurin reduction test Cytotoxicity against human A549 cells by resazurin reduction test	[PMID: 19285391]
A549	IC₅₀	10.82 μM Compound: 7	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20176479]
A549	IC₅₀	11.1 μM Compound: 1	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 20451375]
A549	IC₅₀	11.1 μM Compound: 1	Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A549	IC₅₀	13.3 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
A549	IC₅₀	14.9 μM Compound: 2, BA	Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
A549	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 20034802]
A549	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
A549	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
A549	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24161703]
A549	IC₅₀	146 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 15270560]
A549	IC₅₀	17.13 μM Compound: 2	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
A549	IC₅₀	2.8 μg/mL Compound: 9	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18590313]
A549	IC₅₀	29.5 μM Compound: 1; BA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
A549	IC₅₀	3.1 μM Compound: 17	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay	[PMID: 28358502]
A549	IC₅₀	31 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 23584541]
A549	IC₅₀	3 μg/mL Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18752941]
A549	IC₅₀	43.7 μM Compound: BA	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28368586]
A549	IC₅₀	43.97 μM Compound: Betulinic acid	Cytotoxicity against human A549 cells after 72 hrs ny MTT assay Cytotoxicity against human A549 cells after 72 hrs ny MTT assay	[PMID: 23974020]
A549	IC₅₀	6.65 μM Compound: 3	Cytotoxicity against human A549 cells after 1 hr by MTT assay Cytotoxicity against human A549 cells after 1 hr by MTT assay	[PMID: 18343122]
A549	IC₅₀	69.81 μM Compound: 1; BA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
A549	IC₅₀	72.8 μM Compound: 12	Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge	[PMID: 15730243]
A549	IC₅₀	8 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26629862]
A549	IC₅₀	85.3 μM Compound: 12	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 15730243]
A549	IC₅₀	97.51 μM Compound: BA	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17275295]
A549	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
A549	IC₅₀	> 20 μM Compound: BetA	Cytotoxicity against human A549 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
A549	IC₅₀	> 200 μM Compound: 1	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
B16	ED₅₀	4.1 μM Compound: 11	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	53.46 μM Compound: BA	Cytotoxicity against mouse B16 cells by MTT assay Cytotoxicity against mouse B16 cells by MTT assay	[PMID: 17275295]
B16	IC₅₀	5 μg/mL Compound: 9	Cytotoxicity against mouse B16 cells Cytotoxicity against mouse B16 cells	[PMID: 18590313]
B16	IC₅₀	7.9 μM Compound: 11	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
B16-F10	ED₅₀	4.98 μg/mL Compound: BA (Betulinic acid)	Cytotoxic activity towards B16-F10 cells Cytotoxic activity towards B16-F10 cells	[PMID: 12951080]
B16-F10	IC₅₀	> 20 μM Compound: BetA	Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
BMDC	IC₅₀	19.45 μM Compound: 24	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	21.27 μM Compound: 24	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	3.61 μM Compound: 24	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BRISTOL8	ED₅₀	0.84 μg/mL Compound: Betulinic acid	Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
BV-2	IC₅₀	4.5 μM Compound: 17	Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay	[PMID: 28358502]
BXPC-3	GI₅₀	0.85 μg/mL Compound: 2	Cytotoxicity against human BxPC3 cells Cytotoxicity against human BxPC3 cells	[PMID: 15217278]
Bel-7402	IC₅₀	43.39 μM Compound: BA	Cytotoxicity against human BEL-7402 cells by MTT assay Cytotoxicity against human BEL-7402 cells by MTT assay	[PMID: 17275295]
C3H 10T1/2	IC₅₀	82 μM Compound: 2	Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by fluorometric microculture cytotoxicity assay	[PMID: 18842418]
C6	IC₅₀	90.69 μM Compound: BA	Cytotoxicity against mouse C6 cells by MTT assay Cytotoxicity against mouse C6 cells by MTT assay	[PMID: 17275295]
CCD-18Co	IC₅₀	43.6 μM Compound: 1	Cytotoxicity against human CCD-18Co cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human CCD-18Co cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
CCRF-CEM	ED₅₀	0.98 μg/mL Compound: Betulinic acid	Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
CCRF-CEM	IC₅₀	27 μM Compound: 1	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 15270560]
CCRF-CEM	IC₅₀	30 μM Compound: 1a	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 17371067]
CCRF-CEM	IC₅₀	30 μM Compound: 2	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 22551630]
CEM-SS	CC₅₀	5.9 μM Compound: 5	Cytotoxicity against human CEM-SS cells after 6 days by MTS assay Cytotoxicity against human CEM-SS cells after 6 days by MTS assay	[PMID: 15217281]
CEM-SS	ED₅₀	2 μM Compound: 5	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 15217281]
CHO	EC₅₀	1.04 μM Compound: 1	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
CHO	IC₅₀	> 20 μM Compound: BetA	Cytotoxicity against CHO cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
Ca9-22	IC₅₀	> 20 μg/mL Compound: 9	Cytotoxicity against human sCa9-22 cells by MTT assay Cytotoxicity against human sCa9-22 cells by MTT assay	[PMID: 18590313]
Col2	ED₅₀	43.9 μM Compound: 5	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 15217281]
Col2	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 16562829]
DLD-1	IC₅₀	11.87 μM Compound: 1	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 20451375]
DLD-1	IC₅₀	15 μM Compound: 1	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	15 μM Compound: 2	Cytotoxicity against human DLD1 cells after 48 hrs Cytotoxicity against human DLD1 cells after 48 hrs	[PMID: 19115839]
DLD-1	IC₅₀	15 μM Compound: 3	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 19285391]
DLD-1	IC₅₀	17.5 μM Compound: 2, BA	Cytotoxicity against human DLD1 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
DLD-1	IC₅₀	17.5 μM Compound: BA	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 20034802]
DLD-1	IC₅₀	17.5 μM Compound: BA	Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
DLD-1	IC₅₀	17.5 μM Compound: BA	Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
DLD-1	IC₅₀	> 200 μM Compound: 1	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
DU-145	CC₅₀	> 500 μM Compound: 5	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	ED₅₀	1.13 μg/mL Compound: Betulinic acid	Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
DU-145	GI₅₀	35.3 μg/mL Compound: 1	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18163590]
DU-145	GI₅₀	5 μg/mL Compound: 2	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 15217278]
DU-145	IC₅₀	196 μM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 15270560]
DU-145	IC₅₀	22 μM Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 23584541]
DU-145	IC₅₀	36.16 μM Compound: BA	Cytotoxicity against human DU145 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
DU-145	IC₅₀	37 μM Compound: 2	Cytotoxicity against human DU145 cells after 24 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human DU145 cells after 24 hrs by fluorometric microculture cytotoxicity assay	[PMID: 18842418]
DU-145	IC₅₀	> 20 μg/mL Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 18752941]
DU-145	IC₅₀	> 500 μM Compound: 5	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
Daoy	IC₅₀	11 μM Compound: 1	Cytotoxicity against human DaOY cells after 72 hrs by MTS assay Cytotoxicity against human DaOY cells after 72 hrs by MTS assay	[PMID: 20719505]
Daoy	IC₅₀	31 μM Compound: 7	Antiproliferative activity against human DaOY cells after 72 hrs by MTS assay Antiproliferative activity against human DaOY cells after 72 hrs by MTS assay	[PMID: 19286375]
ECV-304	IC₅₀	1.26 μg/mL Compound: 1, Betulinic acid	Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304 Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304	[PMID: 15081004]
ECV-304	IC₅₀	1.2 μg/mL Compound: 1	Cytotoxic activity against ECV304 (human endothelial) cell line. Cytotoxic activity against ECV304 (human endothelial) cell line.	[PMID: 15149668]
Ehrlich	IC₅₀	54 μM Compound: 1	Cytotoxicity against mouse Ehrlich carcinoma cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse Ehrlich carcinoma cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31499360]
Epithelial cell	IC₅₀	> 20 μM Compound: betulinic acid	Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay	[PMID: 18826277]
FaDu	EC₅₀	10.7 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
FaDu	EC₅₀	13.4 μM Compound: BA	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
FaDu	EC₅₀	13.4 μM Compound: BA	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
FaDu	EC₅₀	13.7 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 28169163]
FaDu	EC₅₀	15.3 μM Compound: 4; BA	Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
FaDu	EC₅₀	15.3 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 26750249]
FaDu	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
FaDu	IC₅₀	10.19 μM Compound: 1	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 20451375]
FaDu	IC₅₀	10.4 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 20034802]
FaDu	IC₅₀	10.4 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
FaDu	IC₅₀	10.4 μM Compound: BA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
Fibroblast	IC₅₀	20.81 μM Compound: 1	Cytotoxicity against human fibroblast after 96 hrs by SRB assay Cytotoxicity against human fibroblast after 96 hrs by SRB assay	[PMID: 20451375]
H9	EC₅₀	1.4 μM Compound: 1	Cytotoxicity against mock-infected human H9 cells Cytotoxicity against mock-infected human H9 cells	[PMID: 11141100]
H9	EC₅₀	1.4 μM Compound: 1	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8176401]
H9	EC₅₀	1.4 μM Compound: 1	Toxic concentration on HIV-1 mock infected H9 lymphocyte cells Toxic concentration on HIV-1 mock infected H9 lymphocyte cells	[PMID: 8676334]
H9	EC₅₀	1.4 μM Compound: 1	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	EC₅₀	1.4 μM Compound: 1, BA	Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication	10.1007/s00044-010-9467-2
H9	EC₅₀	1.4 μM Compound: 1, Betulinic acid	Compound was evaluated for anti-HIV activity in H9 lymphocytes Compound was evaluated for anti-HIV activity in H9 lymphocytes	[PMID: 9871747]
H9	EC₅₀	1.4 μM Compound: 130	Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA	[PMID: 20187635]
H9	EC₅₀	1.4 μM Compound: 130	Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 20187635]
H9	IC₅₀	12.9 μM Compound: 1	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
H9	IC₅₀	12.9 μM Compound: 1, Betulinic acid	Concentration required to produce 50% toxicity against mock-infected H9 cells Concentration required to produce 50% toxicity against mock-infected H9 cells	[PMID: 15501054]
H9	IC₅₀	13 μM Compound: 1	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8176401]
H9	IC₅₀	13 μM Compound: 1	Inhibitory activity against HIV-1 replication in mock infected H9 cells Inhibitory activity against HIV-1 replication in mock infected H9 cells	[PMID: 8676334]
H9	IC₅₀	13 μM Compound: 1	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.	[PMID: 9804704]
H9	IC₅₀	13 μM Compound: 1, Betulinic acid	Compound was evaluated for cytotoxicity in H9 lymphocytes Compound was evaluated for cytotoxicity in H9 lymphocytes	[PMID: 9871747]
H9	IC₅₀	13 μM Compound: 130	Cytotoxicity against human H9 cells after 4 days by coulter counter Cytotoxicity against human H9 cells after 4 days by coulter counter	[PMID: 20187635]
HBL-100	IC₅₀	5.02 μg/mL Compound: 1	Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay	[PMID: 18752941]
HCT-116	GI₅₀	2.7 μM Compound: 1	Cytotoxicity of compound against human colon carcinoma (HCT116) using MTT assay Cytotoxicity of compound against human colon carcinoma (HCT116) using MTT assay	[PMID: 11527742]
HCT-116	IC₅₀	10.8 μM Compound: 1	Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay	[PMID: 20451375]
HCT-116	IC₅₀	13.3 μM Compound: BA	Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay	[PMID: 20034802]
HCT-116	IC₅₀	13.3 μM Compound: BA	Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
HCT-116	IC₅₀	13.3 μM Compound: BA	Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
HCT-116	IC₅₀	13.46 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 3 days by XTT assay Antiproliferative activity against human HCT116 cells after 3 days by XTT assay	[PMID: 19691293]
HCT-116	IC₅₀	22.13 μM Compound: BA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
HCT-116	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
HCT-15	IC₅₀	12 μM Compound: 1	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 23584541]
HCT-15	IC₅₀	14.25 μM Compound: 7	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20176479]
HCT-15	IC₅₀	8.7 μM Compound: 17	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth by SRB assay	[PMID: 28358502]
HCT-8	IC₅₀	13.1 μM Compound: 1	Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay	[PMID: 20451375]
HCT-8	IC₅₀	17.8 μM Compound: BA	Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay	[PMID: 20034802]
HCT-8	IC₅₀	17.8 μM Compound: BA	Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
HCT-8	IC₅₀	17.8 μM Compound: BA	Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
HEK293	CC₅₀	80 μM Compound: 5	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	EC₅₀	> 100 μM Compound: 19	Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay	[PMID: 24955889]
HEK293	IC₅₀	336.2 μM Compound: 5	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	CC₅₀	48.2 μM Compound: 5	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	16 μM Compound: 1	Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay	[PMID: 23584541]
HEp-2	IC₅₀	> 500 μM Compound: 5	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HL-60	IC₅₀	17 μM Compound: 1	Cytotoxicity against human HL60 cells after 48 hrs by SRB assay Cytotoxicity against human HL60 cells after 48 hrs by SRB assay	[PMID: 23584541]
HL-60	IC₅₀	18.47 μM Compound: 2	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
HL-60	IC₅₀	2 μg/mL Compound: 9	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 18590313]
HL-60	IC₅₀	8 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26629862]
HPAF-II	IC₅₀	12.5 μM Compound: 1; BA	Antitumor activity against human HPAF-II cells measured after 72 hrs Antitumor activity against human HPAF-II cells measured after 72 hrs	[PMID: 37236000]
HT-29	EC₅₀	13.1 μM Compound: Betulinic acid	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
HT-29	EC₅₀	14.4 μM Compound: 4; BA	Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
HT-29	EC₅₀	14.4 μM Compound: 5	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 26750249]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 27017553]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 27142753]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29960206]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	EC₅₀	14.4 μM Compound: BA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HT-29	EC₅₀	16 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
HT-29	EC₅₀	18.4 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28169163]
HT-29	EC₅₀	18.4 μM Compound: BA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
HT-29	EC₅₀	18.4 μM Compound: BA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HT-29	EC₅₀	18.4 μM Compound: BA	Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
HT-29	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
HT-29	GI₅₀	30.9 μg/mL Compound: 1	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 18163590]
HT-29	IC₅₀	12.8 μM Compound: 2	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 20494586]
HT-29	IC₅₀	13.93 μM Compound: 1	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 20451375]
HT-29	IC₅₀	13.93 μM Compound: 1	Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
HT-29	IC₅₀	16.1 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 20034802]
HT-29	IC₅₀	16.1 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
HT-29	IC₅₀	16.1 μM Compound: BA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
HT-29	IC₅₀	17.32 μM Compound: BA	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
HT-29	IC₅₀	3.5 μM Compound: 9	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	IC₅₀	31 μM Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 20719505]
HT-29	IC₅₀	37 μM Compound: 7	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 19286375]
HT-29	IC₅₀	89 μM Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 15270560]
HT-29	IC₅₀	> 10 μM Compound: 9	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HUVEC	ED₅₀	28.7 μM Compound: 5	Cytotoxicity against HUVEC cells Cytotoxicity against HUVEC cells	[PMID: 15217281]
HaCaT	IC₅₀	32 μM Compound: 2	Inhibition of GLI1-mediated transcriptional activity in human HaCaT cells by luciferase based reporter gene assay Inhibition of GLI1-mediated transcriptional activity in human HaCaT cells by luciferase based reporter gene assay	[PMID: 18842418]
HeLa	CC₅₀	32.6 μM Compound: 5	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	EC₅₀	8.8 μM Compound: BA	Cytotoxicity against human HeLa cells after 96 hrs by SRB assay Cytotoxicity against human HeLa cells after 96 hrs by SRB assay	[PMID: 27142753]
HeLa	IC₅₀	0.8 μg/mL Compound: betulinicacidbetulinic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 9834149]
HeLa	IC₅₀	10 μM Compound: BA	Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 30 mins by CCK-8 method Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 30 mins by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	10.52 μM Compound: BA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	12.28 μM Compound: BA	Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 20 mins by CCK-8 method Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 20 mins by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	18.24 μM Compound: BA	Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 10 mins by CCK-8 method Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 10 mins by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	26 nM Compound: 2	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19674909]
HeLa	IC₅₀	26 μM Compound: 2	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20494586]
HeLa	IC₅₀	31.27 μM Compound: 1; BA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
HeLa	IC₅₀	35.61 μM Compound: BA	Phototoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 hrs under dark condition by CCK-8 method Phototoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 hrs under dark condition by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	47.6 μM Compound: 5	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
Hep 3B2	IC₅₀	1.7 μg/mL Compound: 9	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 18590313]
HepG2	CC₅₀	> 400 μM Compound: BA	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29326018]
HepG2	IC₅₀	11.74 μM Compound: BA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
HepG2	IC₅₀	21 μM Compound: 12	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	23.9 μM Compound: 1	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25442310]
HepG2	IC₅₀	25.3 μM Compound: 2	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
HepG2	IC₅₀	3.1 μg/mL Compound: 9	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18590313]
HepG2	IC₅₀	36.4 nM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19674909]
HepG2	IC₅₀	36.4 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20494586]
HepG2	IC₅₀	40.03 μM Compound: 1; BA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
HepG2	IC₅₀	5.9 μM Compound: 25	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27617953]
J774	IC₅₀	44 μM Compound: 9	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
Jurkat	ED₅₀	0.65 μg/mL Compound: Betulinic acid	Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay	[PMID: 15225732]
Jurkat	IC₅₀	26.9 nM Compound: 2	Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay	[PMID: 19674909]
Jurkat	IC₅₀	26.9 μM Compound: 2	Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay	[PMID: 20494586]
K562	GI₅₀	10.8 μg/mL Compound: 1	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 18163590]
K562	IC₅₀	112 μM Compound: 1	Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay	[PMID: 15270560]
K562	IC₅₀	21.96 μM Compound: 2	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
K562	IC₅₀	3.25 μg/mL Compound: 1	Cytotoxicity against human K-562 cells after 72 hrs by MTT assay Cytotoxicity against human K-562 cells after 72 hrs by MTT assay	[PMID: 18752941]
K562	IC₅₀	56 μM Compound: 1	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 15270560]
KB	CC₅₀	15.6 μM Compound: 5	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	ED₅₀	35.7 μM Compound: 5	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15217281]
KB	ED₅₀	> 20 μg/mL Compound: 1	In vitro cytotoxicity (antitumor activity) against human epidermoid carcinoma of mouth cell line (KB) In vitro cytotoxicity (antitumor activity) against human epidermoid carcinoma of mouth cell line (KB)	[PMID: 10328313]
KB	ED₅₀	> 20 μg/mL Compound: 1	Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line. Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.	[PMID: 9873420]
KB	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against drug-resistant human KB cells in absence of vinblastine Cytotoxicity against drug-resistant human KB cells in absence of vinblastine	[PMID: 16562829]
KB	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against drug-resistant human KB cells in presence of vinblastine Cytotoxicity against drug-resistant human KB cells in presence of vinblastine	[PMID: 16562829]
KB	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 16562829]
KB	IC₅₀	27.5 μM Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 25442310]
KB	IC₅₀	28.1 μM Compound: 5	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	28.7 μM Compound: 1; BA	Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
KM-20L2	GI₅₀	3.4 μg/mL Compound: 2	Cytotoxicity against human KM20L2 cells Cytotoxicity against human KM20L2 cells	[PMID: 15217278]
L02	IC₅₀	35.07 μM Compound: 2	Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
L132	ED₅₀	1.3 μg/mL Compound: Betulinic acid	Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
LN-229	IC₅₀	29 μM Compound: 1	Cytotoxicity against human LN229 cells after 72 hrs by MTS assay Cytotoxicity against human LN229 cells after 72 hrs by MTS assay	[PMID: 20719505]
LN-229	IC₅₀	61 μM Compound: 7	Antiproliferative activity against human LN229 cells after 72 hrs by MTS assay Antiproliferative activity against human LN229 cells after 72 hrs by MTS assay	[PMID: 19286375]
LNCaP	ED₅₀	27.4 μM Compound: 5	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15217281]
LNCaP	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human LNCaP cells Cytotoxicity against human LNCaP cells	[PMID: 16562829]
Lu1	ED₅₀	40.6 μM Compound: 5	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15217281]
Lu1	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 16562829]
M14	GI₅₀	2.7 μM Compound: 1	Cytotoxicity of compound against human melanoma cell lines (M14-MEL) using MTT assay Cytotoxicity of compound against human melanoma cell lines (M14-MEL) using MTT assay	[PMID: 11527742]
M14	GI₅₀	32.6 μg/mL Compound: 1	Cytotoxicity against human M14 cells Cytotoxicity against human M14 cells	[PMID: 18163590]
M14	IC₅₀	50 μM Compound: 4	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
MCF7	CC₅₀	49.6 μM Compound: 5	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	EC₅₀	10.2 μM Compound: 1	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26547057]
MCF7	EC₅₀	10.2 μM Compound: 4; BA	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
MCF7	EC₅₀	10.2 μM Compound: 5	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	10.2 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26750249]
MCF7	EC₅₀	10.2 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 27017553]
MCF7	EC₅₀	10.2 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	EC₅₀	10.2 μM Compound: BA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MCF7	EC₅₀	10.6 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
MCF7	EC₅₀	11.4 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28169163]
MCF7	EC₅₀	12 μM Compound: BA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	EC₅₀	12 μM Compound: BA	Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
MCF7	EC₅₀	14.8 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 27142753]
MCF7	EC₅₀	14.8 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29960206]
MCF7	EC₅₀	14.9 μM Compound: Betulinic acid	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
MCF7	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
MCF7	GI₅₀	1.1 μg/mL Compound: 2	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 15217278]
MCF7	GI₅₀	11.3 μM Compound: Betulinic acid	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	GI₅₀	> 62.5 μg/mL Compound: 1	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18163590]
MCF7	IC₅₀	0.33 μM Compound: 1	Antitumor activity against human MCF7 cells by SRB assay Antitumor activity against human MCF7 cells by SRB assay	[PMID: 31499360]
MCF7	IC₅₀	10.527 μM Compound: BetA	Cytotoxicity against human MCF7 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
MCF7	IC₅₀	12.27 μM Compound: 1	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 20451375]
MCF7	IC₅₀	12.27 μM Compound: 1	Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
MCF7	IC₅₀	14.03 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
MCF7	IC₅₀	14.03 μM Compound: 102	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by SRB assay	[PMID: 38308950]
MCF7	IC₅₀	14.8 μM Compound: 2, BA	Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
MCF7	IC₅₀	14.8 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24161703]
MCF7	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 20034802]
MCF7	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
MCF7	IC₅₀	14.9 μM Compound: BA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
MCF7	IC₅₀	143 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 15270560]
MCF7	IC₅₀	16.4 μM Compound: 102	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs under hypoxic condition by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs under hypoxic condition by SRB assay	[PMID: 38308950]
MCF7	IC₅₀	22.61 μM Compound: BA	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
MCF7	IC₅₀	30 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 20719505]
MCF7	IC₅₀	37 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 23584541]
MCF7	IC₅₀	41 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 19115839]
MCF7	IC₅₀	41 μM Compound: 3	Cytotoxicity against human MCF7 cells by resazurin reduction test Cytotoxicity against human MCF7 cells by resazurin reduction test	[PMID: 19285391]
MCF7	IC₅₀	4 μg/mL Compound: 9	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18590313]
MCF7	IC₅₀	50 μM Compound: 7	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 19286375]
MCF7	IC₅₀	54.8 μM Compound: 1; BA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
MCF7	IC₅₀	56.3 μM Compound: 5	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
MCF7	IC₅₀	> 25 μM Compound: BA	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability by trypan blue test Cytotoxicity against human MCF7 cells assessed as decrease in cell viability by trypan blue test	[PMID: 30108714]
MCF7	IC₅₀	> 30 μM Compound: BA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
MCF7	IC₅₀	> 40 μM Compound: 1; BA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
MDA-MB-231	CC₅₀	94.3 μM Compound: 5	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	GI₅₀	22.9 μM Compound: Betulinic acid	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	15.24 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 19691293]
MDA-MB-231	IC₅₀	19.13 μM Compound: Betulinic acid	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35217359]
MDA-MB-231	IC₅₀	28.85 μM Compound: BA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
MDA-MB-231	IC₅₀	3.5 μg/mL Compound: 9	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 18590313]
MDA-MB-231	IC₅₀	34.57 μM Compound: BA	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
MDA-MB-231	IC₅₀	> 10 μM Compound: 9	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-231	IC₅₀	> 20 μM Compound: BetA	Cytotoxicity against human MDA-MB-231 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
MDA-MB-231	IC₅₀	> 40 μM Compound: 1; BA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
MDA-MB-231	IC₅₀	> 500 μM Compound: 5	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
ME-180	GI₅₀	27.8 μg/mL Compound: 1	Cytotoxicity against human ME180 cells Cytotoxicity against human ME180 cells	[PMID: 18163590]
MIA PaCa-2	IC₅₀	26.7 μM Compound: Betulinic acid	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35217359]
MIA PaCa-2	IC₅₀	7 μM Compound: 1	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26629862]
MIA PaCa-2	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
MIA PaCa-2	IC₅₀	> 20 μg/mL Compound: 1	Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay	[PMID: 18752941]
MOLT-4	ED₅₀	1.23 μg/mL Compound: Betulinic acid	Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
MRC5	IC₅₀	32.8 μM Compound: BA	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28368586]
NCI-H460	GI₅₀	29.7 μg/mL Compound: 1	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 18163590]
NCI-H460	GI₅₀	4.7 μg/mL Compound: 2	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 15217278]
NCI/ADR-RES	IC₅₀	38.5 μM Compound: BA	Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
NIH3T3	EC₅₀	10 μM Compound: Betulinic acid	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 26211461]
NIH3T3	EC₅₀	12.9 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
NIH3T3	EC₅₀	13.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28169163]
NIH3T3	EC₅₀	13.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 29960206]
NIH3T3	EC₅₀	16.1 μM Compound: 1	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26547057]
NIH3T3	EC₅₀	16.1 μM Compound: 4; BA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
NIH3T3	EC₅₀	16.1 μM Compound: 5	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26750249]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 27017553]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
NIH3T3	EC₅₀	16.1 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
NIH3T3	EC₅₀	> 30 μM Compound: 1	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
NIH3T3	GI₅₀	> 62.5 μg/mL Compound: 1	Cytotoxicity against BALB/c mouse 3T3 cells Cytotoxicity against BALB/c mouse 3T3 cells	[PMID: 18163590]
NIH3T3	IC₅₀	10 μM Compound: 2, BA	Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
NIH3T3	IC₅₀	10 μM Compound: BA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24161703]
NIH3T3	IC₅₀	4.37 μg/mL Compound: 1	Cytotoxicity against mouse NIH3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse NIH3T3 cells after 72 hrs by MTT assay	[PMID: 18752941]
NIH3T3	IC₅₀	> 20 μM Compound: BetA	Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
Neutrophil	IC₅₀	11.12 μg/mL Compound: 2	Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay	10.1007/s00044-012-0183-y
OVCAR-3	IC₅₀	0.9 μg/mL Compound: betulinicacidbetulinic acid	Cytotoxicity against human OVCAR-3 cells after 48 hrs by MTT assay Cytotoxicity against human OVCAR-3 cells after 48 hrs by MTT assay	[PMID: 9834149]
OVCAR-3	IC₅₀	40 μM Compound: 1	Cytotoxicity against human OVCAR-3 cells after 72 hrs by MTS assay Cytotoxicity against human OVCAR-3 cells after 72 hrs by MTS assay	[PMID: 20719505]
OVCAR-3	IC₅₀	59 μM Compound: 7	Antiproliferative activity against human OVCAR-3 cells after 120 hrs by MTS assay Antiproliferative activity against human OVCAR-3 cells after 120 hrs by MTS assay	[PMID: 19286375]
OVCAR-3	IC₅₀	8.366 μM Compound: BetA	Cytotoxicity against human OVCAR3 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human OVCAR3 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
P388	GI₅₀	> 10 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 15217278]
P815	IC₅₀	41 μM Compound: 1	Cytotoxicity against mouse P815 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse P815 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31499360]
PA-1	ED₅₀	> 10 μg/mL Compound: Betulinic acid	Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
PA-1	IC₅₀	11.53 μg/mL Compound: 1	Cytotoxicity against human PA-1 cells after 72 hrs by MTT assay Cytotoxicity against human PA-1 cells after 72 hrs by MTT assay	[PMID: 18752941]
PANC-1	IC₅₀	10.223 μM Compound: BetA	Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
PANC-1	IC₅₀	32 μM Compound: 138	Inhibition of Gli1-mediated transcription expressed in human PANC1 cells Inhibition of Gli1-mediated transcription expressed in human PANC1 cells	[PMID: 19309080]
PANC-1	IC₅₀	44 μM Compound: 2	Cytotoxicity against human PANC1 after 24 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human PANC1 after 24 hrs by fluorometric microculture cytotoxicity assay	[PMID: 18842418]
PC-3	EC₅₀	1.9 mM Compound: 1	Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay	[PMID: 11527742]
PC-3	GI₅₀	31.3 μg/mL Compound: 1	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 18163590]
PC-3	IC₅₀	21.5 μM Compound: 2	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20494586]
PC-3	IC₅₀	27.51 μM Compound: BA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
PC-3	IC₅₀	37 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 23584541]
PC-3	IC₅₀	40 μM Compound: 2	Cytotoxicity against human PC3 cells after 48 hrs Cytotoxicity against human PC3 cells after 48 hrs	[PMID: 19115839]
PC-3	IC₅₀	40 μM Compound: 3	Cytotoxicity against human PC3 cells by resazurin reduction test Cytotoxicity against human PC3 cells by resazurin reduction test	[PMID: 19285391]
PC-3	IC₅₀	7 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26629862]
PC-3	IC₅₀	91 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 15270560]
PC-3	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
PC-3	IC₅₀	> 100 μM Compound: 1; BA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
RAW264.7	CC₅₀	50.64 μM Compound: BA	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured for 96 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured for 96 hrs by MTT assay	[PMID: 34491054]
RAW264.7	IC₅₀	32.38 μM Compound: BA	Inhibition of RANKL/M-CSF-induced osteoclastogenesis in mouse RAW264.7 cells measured for 4 days by TRAP staining based assay Inhibition of RANKL/M-CSF-induced osteoclastogenesis in mouse RAW264.7 cells measured for 4 days by TRAP staining based assay	[PMID: 34491054]
RAW264.7	IC₅₀	42.5 μM Compound: 110	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 31255927]
RAW264.7	IC₅₀	> 100 μM Compound: 4	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 34800877]
RD	IC₅₀	23.95 μM Compound: Betulinic acid	Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay	[PMID: 23974020]
Raji	IC₅₀	403 molar ratio Compound: 1	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA	[PMID: 19481937]
SF-268	GI₅₀	0.86 μg/mL Compound: 2	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 15217278]
SF-295	IC₅₀	22 μM Compound: 1	Cytotoxicity against human SF295 cells after 48 hrs by SRB assay Cytotoxicity against human SF295 cells after 48 hrs by SRB assay	[PMID: 23584541]
SH-SY5Y	EC₅₀	4.3 μM Compound: Betulinic acid	Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 1-methyl-4-phenylpyridinium ion-induced cell death after 48 hrs by MTT assay Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 1-methyl-4-phenylpyridinium ion-induced cell death after 48 hrs by MTT assay	[PMID: 27420919]
SK-MEL	IC₅₀	35 μM Compound: 2	Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL	[PMID: 10450948]
SK-MEL-2	EC₅₀	2.2 mM Compound: 1	Cytotoxicity of compound against SK-MEL-2 using SRB assay Cytotoxicity of compound against SK-MEL-2 using SRB assay	[PMID: 11527742]
SK-MEL-2	ED₅₀	1.2 μg/mL Compound: 1	Cytotoxicity against cultured human melanoma (MEL-2) cell line. Cytotoxicity against cultured human melanoma (MEL-2) cell line.	[PMID: 9873420]
SK-MEL-2	ED₅₀	1.3 μM Compound: 5	Cytotoxicity against human SK-MEL-2 cells Cytotoxicity against human SK-MEL-2 cells	[PMID: 15217281]
SK-MEL-2	ED₅₀	4.2 μg/mL Compound: 1	In vitro cytotoxicity (antitumor activity) against human melanoma (MEL-2) cell lines In vitro cytotoxicity (antitumor activity) against human melanoma (MEL-2) cell lines	[PMID: 10328313]
SK-MEL-2	ED₅₀	7.62 μg/mL Compound: BA (Betulinic acid)	Cytotoxic activity towards M2 cells (SK-MEL-2) Cytotoxic activity towards M2 cells (SK-MEL-2)	[PMID: 12951080]
SK-MEL-2	GI₅₀	3.2 μM Compound: 1	Cytotoxicity of compound against human melanoma cell lines (SK-MEL-2) using MTT assay Cytotoxicity of compound against human melanoma cell lines (SK-MEL-2) using MTT assay	[PMID: 11527742]
SK-MEL-2	IC₅₀	17.44 μM Compound: 7	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20176479]
SK-MEL-2	IC₅₀	21 μM Compound: 1	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 15270560]
SK-MEL-2	IC₅₀	33 μM Compound: 7	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTS assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTS assay	[PMID: 19286375]
SK-MEL-2	IC₅₀	7 μM Compound: 1	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTS assay	[PMID: 20719505]
SK-MEL-2	IC₅₀	> 10 μM Compound: 17	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth by SRB assay	[PMID: 28358502]
SK-N-SH	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human SKNSH cells Cytotoxicity against human SKNSH cells	[PMID: 16562829]
SK-OV-3	IC₅₀	17.68 μM Compound: 7	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20176479]
SK-OV-3	IC₅₀	> 10 μM Compound: 17	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 28358502]
SMMC-7721	IC₅₀	43.6 μM Compound: 1; BA	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
SW-1736	EC₅₀	14.8 μM Compound: BA	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine-B assay	[PMID: 30056282]
SW-1736	EC₅₀	16.4 μM Compound: BA	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
SW-1736	EC₅₀	16.4 μM Compound: BA	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
SW-1736	EC₅₀	16.4 μM Compound: BA	Anticancer activity against human SW1736 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human SW1736 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
SW-1736	EC₅₀	18.3 μM Compound: BA	Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay	[PMID: 29960206]
SW-1736	IC₅₀	11.6 μM Compound: 2, BA	Cytotoxicity against human SW1736 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23245801]
SW-1736	IC₅₀	11.6 μM Compound: BA	Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay	[PMID: 20034802]
SW-1736	IC₅₀	11.6 μM Compound: BA	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
SW-1736	IC₅₀	11.6 μM Compound: BA	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
SW-1736	IC₅₀	13.09 μM Compound: 1	Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay	[PMID: 20451375]
SW-1736	IC₅₀	13.09 μM Compound: 1	Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
SW-620	IC₅₀	13.26 μg/mL Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 18752941]
SW-620	IC₅₀	54.34 μM Compound: 1; BA	Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
SW480	IC₅₀	6.4 μM Compound: BA	Cytotoxicity against human SW480 cells after 96 hrs by SRB assay Cytotoxicity against human SW480 cells after 96 hrs by SRB assay	[PMID: 20034802]
SW480	IC₅₀	6.4 μM Compound: BA	Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay	[PMID: 20299226]
SW480	IC₅₀	6.4 μM Compound: BA	Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay	[PMID: 20846866]
SW480	IC₅₀	6.48 μM Compound: 1	Cytotoxicity against human SW480 cells after 96 hrs by SRB assay Cytotoxicity against human SW480 cells after 96 hrs by SRB assay	[PMID: 20451375]
SW626	ED₅₀	> 20 μg/mL Compound: betulinic acid	Cytotoxicity against human SW626 cells Cytotoxicity against human SW626 cells	[PMID: 16562829]
SW948	IC₅₀	10.5 μM Compound: 1	Antiproliferative activity against human SW948 cells after 3 days by XTT assay Antiproliferative activity against human SW948 cells after 3 days by XTT assay	[PMID: 19691293]
SiHa	CC₅₀	28.9 μM Compound: 5	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	70.1 μM Compound: 5	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
T47D	IC₅₀	15.56 μM Compound: BA	Cytotoxicity against human T47D cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human T47D cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
THP-1	IC₅₀	20 μM Compound: 1	Cytotoxicity against human THP1 cells after 48 hrs by SRB assay Cytotoxicity against human THP1 cells after 48 hrs by SRB assay	[PMID: 23584541]
U-937	ED₅₀	0.69 μg/mL Compound: Betulinic acid	Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
UACC-257	GI₅₀	1.5 μM Compound: 1	Cytotoxicity of compound against human melanoma cell lines (UACC-257) using MTT assay Cytotoxicity of compound against human melanoma cell lines (UACC-257) using MTT assay	[PMID: 11527742]
Vero	CC₅₀	150 μM Compound: 13	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	CC₅₀	38.1 μM Compound: 5	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	CC₅₀	> 100 μM Compound: 1, Betulinic acid	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by Alamar Blue assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by Alamar Blue assay	[PMID: 26112446]
Vero	CC₅₀	> 400 μM Compound: BA	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29326018]
Vero	EC₅₀	> 10 μM Compound: 13	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	GI₅₀	30.6 μg/mL Compound: 1	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 18163590]
Vero	IC₅₀	1.6 μM Compound: 1, Betulinic acid	Antiviral activity against HSV-2 186 infected in African green monkey Vero cells assessed as inhibition of viral yield after 48 hrs by crystal violet staining Antiviral activity against HSV-2 186 infected in African green monkey Vero cells assessed as inhibition of viral yield after 48 hrs by crystal violet staining	[PMID: 26112446]
Vero	IC₅₀	72.1 μM Compound: 5	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
WI-38	IC₅₀	1.3 μM Compound: 12	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	11.6 μM Compound: 12	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]

In Vitro

Betulinic acid is a eukaryotic topoisomerase I inhibitor, with an IC₅₀ of 5 μM, and prevents topoisomerase I-DNA interaction^[1]. Betulinic acid (10, 20, 40, 80, and 160 μM) significantly suppresses MDA-MB-231 cell viability in a time- and dose-dependent manner after treatment for 24 or 48 h. Betulinic acid (20, 40 μM) causes decrease in Bcl-2 expression of MDA-MB-231 cells. Betulinic acid also induces morphological changes of MDA-MB-231 cells at 20 μM, and leads to ultrastructure changes of MDA-MB-231 cells at 40 μM^[2]. Betulinic acid shows anti-HIV activities, with an EC₅₀ of 1.4 μM in acutely infected H9 lymphocytes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Betulinic acid (10 and 30 mg/kg, p.o.) significantly abrogates colon shortening, and reduces malondialdehyde (MDA) and lipid hydroperoxide levels in dextran sulfate sodium (DSS)-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) restores superoxide dismutase (SOD), catalase activity and glutathione (GSH) content to control levels in DSS-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) also inhibits the DSS-induced increase in inflammatory markers. Betulinic acid (3, 10, 30 mg/kg, p.o.) suppresses acetic acid-induced writhing responses and mustard oil (MO)-induced visceral nociception in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

456.70

Formula

C₃₀H₄₈O₃

CAS No.

472-15-1

Appearance

Solid

Color

White to off-white

SMILES

[H][C@@]12CC[C@@]3(C)[C@]4(C)CC[C@]5(C(O)=O)[C@@]([C@H](C(C)=C)CC5)([H])[C@@](CC[C@@]([H])3[C@@]1(C)CC[C@H](O)C2(C)C)4[H]

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 11.67 mg/mL (25.55 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1896 mL	10.9481 mL	21.8962 mL
5 mM	0.4379 mL	2.1896 mL	4.3792 mL
10 mM	0.2190 mL	1.0948 mL	2.1896 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.33 mg/mL (2.91 mM); Clear solution

This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 4 mg/mL (8.76 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 2 mg/mL (4.38 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (284 KB) SDS (396 KB)

COA (253 KB) HNMR (276 KB) RP-HPLC (244 KB) MS (232 KB)

Handling Instructions (2659 KB)

References

[1]. Chowdhury AR, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002 Jul;8(7):BR254-65. [Content Brief]

[2]. Gao Y, et al. Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jan-Feb;42(1):49-54. [Content Brief]

[3]. Kalra J, et al. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec 26. [Content Brief]

[4]. Hashimoto F, et al. Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem. 1997 Dec;5(12):2133-43. [Content Brief]

[5]. Kasperczyk H, et al. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005 Oct 20;24(46):6945-56. [Content Brief]

[6]. Fernandes S, et al. Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives. Int J Mol Sci. 2024 Feb 9;25(4):2108. [Content Brief]

Cell Assay ^[2]	CCK-8 is used in the assay. MDA-MB-231 cells are cultured in 96-well plates at a density of 2 × 10³ cells/well and then treated with DMSO vehicle or various concentrations of Betulinic acid ranging from 5 µM to 160 µM in 100 µL of medium for the indicated times. After the treatment period, the medium in each well is replaced with 110 µL of medium containing 10 µL of the CCK-8 mixture, and the plates are incubated for 1 h and 30 min at 37°C. The absorbance at a wavelength of 450 nm is measured with a microplate reader^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Female Swiss albino mice are administered vehicle (5% v/v DMSO in peanut oil) or Betulinic acid (3, 10 or 30 mg/kg) in vehicle, orally. After 1 h, acetic acid (300 mg/kg) is administered by intraperitoneal route and number of writhing response of each animal is counted for 20 min by an observer who is blind to the treatments. Writhing response is when animal rubs its abdomen on surface of table/floor with elongation of the body and extension of the hind limbs^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Chowdhury AR, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002 Jul;8(7):BR254-65. [Content Brief] [2]. Gao Y, et al. Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jan-Feb;42(1):49-54. [Content Brief] [3]. Kalra J, et al. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec 26. [Content Brief] [4]. Hashimoto F, et al. Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem. 1997 Dec;5(12):2133-43. [Content Brief] [5]. Kasperczyk H, et al. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005 Oct 20;24(46):6945-56. [Content Brief] [6]. Fernandes S, et al. Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives. Int J Mol Sci. 2024 Feb 9;25(4):2108. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1896 mL	10.9481 mL	21.8962 mL	54.7405 mL
	5 mM	0.4379 mL	2.1896 mL	4.3792 mL	10.9481 mL
	10 mM	0.2190 mL	1.0948 mL	2.1896 mL	5.4741 mL
	15 mM	0.1460 mL	0.7299 mL	1.4597 mL	3.6494 mL
	20 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	25 mM	0.0876 mL	0.4379 mL	0.8758 mL	2.1896 mL

Betulinic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Betulinic acid472-15-1Lupatic acid Betulic acidApoptosisTopoisomeraseHIVAutophagyMitophagyNF-κBEndogenous MetaboliteParasiteHuman immunodeficiency virusMitochondrial AutophagyNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Betulinic acid (Synonyms: Lupatic acid; Betulic acid)

Customer Review

Other Forms of Betulinic acid:

Betulinic acid Related Antibodies

35 Publications Citing Use of MCE Betulinic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All HIV Isoform Specific Products:

View All NF-κB Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

View All Parasite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Betulinic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Betulinic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report